跳至主要内容
临床试验/NCT06868589
NCT06868589已完成4 期

Randomized Clinical Trial of Methadone and Ketamine for Pain Management During Deceased Donor Liver Transplant

Lahey Clinic3 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年6月30日最近更新:
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Lahey Clinic
入组人数
50
试验地点
3
主要终点
Postoperative Pain

研究概览

简要总结

The goal of this clinical trial is to learn if using methadone and ketamine during an adult deceased donor liver transplant can help decrease pain after surgery.

The main questions it aims to answer are:

  • What impact does using methadone and ketamine during a deceased donor liver transplant have on pain after surgery?
  • Does the use of methadone and ketamine also have an impact on mental confusion (delirium) after surgery?

Researchers will compare the use of methadone and ketamine to standard of care to see if the two drugs work to decrease pain and impact delirium after liver transplant.

Participants will:

  • Receive either methadone and ketamine or standard of care during their deceased donor liver transplant.
  • Allow researchers to follow medical care throughout inpatient stay.

详细描述

Pain control following liver transplantation (LT) has been the subject of interest of many research projects due to invasive nature of the procedure, significant comorbidities of recipients, effect of hepatic metabolism on many common pain medications and difficulties in performing some neuraxial and regional techniques given patient coagulopathy. Some newer regional nerve blocks such as External Oblique Intercostal (EOI) block has also been successfully utilized in pain management of patients undergoing liver resections but their utilization in perioperative setting for high-MELD patients and after-hour operations are limited. Methadone and ketamine are well-known drugs that have been recently emerged as components of new pain management pathways in many open surgeries due to their availability, cost, well-known metabolism, good safety profile and prolonged effects. Evidence has emerged that their use is associated with decreased likelihood of development of chronic pain and need for long term opioids. The combination of methadone and ketamine has been shown to be superior to opioids alone due to synergistic effect on N-methyl-d-aspartate and μ-opioid receptors. But these medications have not been extensively studied in LT recipients except for a few case reports and small studies. Current standards of care for intraoperative pain management during LT are systemic short and medium long-acting opioids such as fentanyl and hydromorphone which both have numerous concerns such as respiratory depression and opioid dependency. The aim of this study is to prospectively evaluate the effect of intraoperative methadone and ketamine administration on postoperative pain in liver transplant recipients. These drugs have been safely used during liver transplantation at LHMC and other centers and showed to be effective and safe, but the exact dosing and timing of administration requires further studies.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

盲法说明

Participants won't be aware of the study arm and treatments they receive. The statistician will be masked on the treatment group during final study analysis.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients ≥ 18 years of age at the time of LT.
  • Undergoing LT from a deceased donor.
  • Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

排除标准

  • Living donor liver transplantation (LDLT).
  • Split liver transplantation (isolated right or left lobe).
  • Acute liver failure (ALF) as the indication for LT.
  • Repeat (redo) liver transplant
  • Simultaneous liver and kidney transplant (SLK)
  • Sedation or high vasopressor use.
  • Subject is intubated and/or mechanically ventilated prior to entering the operating room for LT.
  • Severe Hepatic encephalopathy
  • History of psychiatric disorders such as schizophrenia or bipolar mood disorders
  • History of chronic opioid use, substance abuse or opioid maintenance therapies
  • Any history of allergic reaction to any of the study drugs History of Brugadda, prolonged QT syndrome or QTc in preoperative setting
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
  • Pregnant person
  • Operational Exclusion Criterion: Subjects will not be enrolled if study personnel required for protocol execution (e.g., study investigator, research staff or pharmacy staff) are unavailable at the time of transplantation.

研究组 & 干预措施

SOC group

Active Comparator

Participants in this arm will receive the standard of care with combination of hydromorphone and fentanyl

干预措施: Hydromorphone (Drug)

M+K group

Experimental

Participants in this arm will receive the intervention with methadone and ketamine

干预措施: ketamine (Drug)

M+K group

Experimental

Participants in this arm will receive the intervention with methadone and ketamine

干预措施: Methadone (Drug)

SOC group

Active Comparator

Participants in this arm will receive the standard of care with combination of hydromorphone and fentanyl

干预措施: fentanyl (Drug)

结局指标

主要结局

Postoperative Pain

时间窗: 8, 16, 24, 32, 40 and 48hours post-surgery finish

postoperative opioid consumption (measured as morphine milligram equivalents ((MME)) 48 hours after surgery

次要结局

  • Postoperative adjunct pain modalities(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Length of stay in intensive care unit(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Length of stay in hospital(Post surgery finish until discharge from hospital, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Delirium(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Respiratory complications(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Narcotics reversal agent(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Length of stay in intensive care unit(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Length of stay in hospital(Post surgery finish until discharge from hospital, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Delirium(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Respiratory complications(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Narcotics reversal agent(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Postoperative adjunct pain modalities(Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days)
  • Correlation Between Study Drug Exposure and Early Post-Transplant Laboratory Markers of Liver Dysfunction(Immediate to 24hrs post surgery finish)
  • Correlation Between Donor and Surgical Factors and Postoperative Opioid Use (MME)(From the end of surgery through 48hr post surgery)

研究者

发起方
Lahey Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ryan Nazemian

Staff Anesthesiologist: Division of Transplant, Director: Transplant Anesthesia Fellowship, Co-Director: Anesthesia Informatics

Lahey Clinic

研究点 (3)

Loading locations...

相似试验